medigraphic.com
ISSN 2594-1526 (Digital)
ISSN 0028-3746 (Impreso)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2007, Número S2

<< Anterior Siguiente >>

Neumol Cir Torax 2007; 66 (S2)


Manejo del paciente con epoc inestable. Exacerbación leve, moderada y grave

Definición de la EAEPOC (Exacerbación aguda de la Enfermedad Pulmonar Obstructiva Crónica)
Causas de la EAEPOC
Diagnóstico de la EAEPOC
Síntomas de la EAEPOC
Hallazgos físicos EAEPOC
Diagnóstico diferencial EAEPOC
Clasificación de la EAEPOC de acuerdo a la gravedad
Tratamiento integral de las EAEPOC
Tratamiento farmacológico para el manejo de las EAEPOC
Tratamiento farmacológico adyuvante y otras medidas
Tratamiento no farmacológico de la EAEPOC
Educación para la salud en EAEPOC
Rehabilitación respiratoria en EAEPOC

Idioma: Español
Referencias bibliográficas: 100
Paginas: 54-70
Archivo PDF: 117.94 Kb.


RESUMEN

Exacerbación aguda de la enfermedad pulmonar obstructiva crónica (EAEPOC)

INTRODUCCIÓN

Siendo la EPOC un padecimiento heterogéneo caracterizado por la pérdida progresiva de la función pulmonar y limitación física, debe agregarse la presencia de las EAEPOC, en las cuales el paciente puede agravarse por periodos de días a semanas, incluso puede encontrar la muerte.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21: 46S-53S.

  2. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.

  3. Wouters EF. The burden of COPD in the Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97: S51-S59.

  4. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 446-52.

  5. Kanner RE, Anthonisen NR, Connett JE. The Lung Health Study research Group. Lower respiratory illnesses promote FEV1 decline in currect smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-364.

  6. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648.

  7. Connors AF, Jr., Dawson NV, Thomas C, Harrell FE, Jr., Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigations (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959-967. Errata en: Am J Respir Crit Care Med 1997; 155: 386.

  8. Mac Nee W. Pathophysiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. In: Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 29-49.

  9. Rodríguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S-401S.

  10. Anthonisen NR. Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.

  11. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.

  12. Piquette CA, Rennard SI. Assessment of Severity of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. In: Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 203-227.

  13. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-31.

  14. Hurst JR, Wedzicha JA. Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation. Postgrad Med J 2004; 80: 497-505

  15. Tellez-Rojo MM, Romieu I, Ruiz-Velasco S, Lezana MA, Hernandez-Avila MM. Daily respiratory mortality and PM10 in México City. Importance of consider the place of death. Eur Respir J 2000; 16: 391-396.

  16. Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26-33.

  17. Parker CM, Voduc N, Aaron SD, Webb KA, O’Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26: 420-428.

  18. Gomez FP, Rodriguez-Roisin R. Pulmonary Gas Exchange in Exacerbations of Chronic Obstructive Pulmonary Disease. In: Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 137-159.

  19. Groenewegen KH, Schols AMWJ, Wouters EFM. Mortality and Mortality-Related Factors After Hospitalization for Acute Exacerbation of COPD. Chest 2003; 124: 459-467.

  20. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.

  21. Hurst JR, Donaldson GC, Perera WR, Wilkinson MA, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2006; 174: 867-874. Véase Editorial Müller B, Tamm M. Biomarkers in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Among the Blind, the One-eyed is King. Am J Respir Crit Care Med 2006; 174: 848-849.

  22. Clague JE, Carter J, Pearson MG, Calverley PMA. Physiological determinants of inspiratory effort sensation during CO2 rebreathing in normal subjects. Clin Sci 1993; 85: 637-642.

  23. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1654.

  24. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003; 58: 73-80.

  25. Sapey E, Stockley RA. COPD exacerbations. 2: Aetiology. Thorax 2006; 61: 250-258.

  26. Miravitles M, Espinosa C, Fernandes-Laso E, Martos JA, Maldonado JA, Gallego M, and study group of bacterial infections in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40-46.

  27. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.

  28. Standars fot the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77-S121.

  29. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52: S1-S28.

  30. Siafakas NM, Wedzicha JA. Management of acute exacerbation of chronic obstructive pulmonary disease. Eur Respir Mon 2006; 38: 387-400.

  31. Brunton S, Carmichael BP, Colgan R, Feeney AS, Fendrick AM, Quintiliani R, Scott G. Acute Exacerbation of Chronic Bronchitis: A Primary Care Consensus Guideline. Am J Manag Care 2004; 10: 689-696.

  32. Sharma S, Anthonisen NR. In: Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 331-344.

  33. Adkison JD, Konzerm SL. Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Pharmacotherapy 2001; 21: 929-939.

  34. Rodríguez-Roisin R. COPD exacerbations. Management. Thorax 2006; 61: 535-544. Cuadros en el siguiente sitio web: http://www.thoraxjnl.com/supplemental.

  35. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411-1419.

  36. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.

  37. Tzoufi M, Mentzelopoulos SD, Roussos C, Armaganidis A. The effect of nebulized salbutamol, external positive end-expiratory pressure, and their combination on respiratory mechanics, hemodynamics, and gas exchange in mechanically ventilated chronic obstructive pulmonary disease patients. Anesth Analg 2005; 101: 843-850.

  38. Dhand R. Inhalation therapy in invasive and noninvasive mechanical ventilation. Curr Opin Crit Care 2007; 13: 27-38.

  39. Bennett WD. Effects of beta-adrenergic agonists on mucociliary clearence. J Allergy Clin Immunol 2002; 110: S291-S297.

  40. Berry BB, Shinto RA, Wong FH, Despars JA, Light RW. Nebulized versus spacer for bronchodilator delivery in patients hospitalized for acute exacerbation of COPD. Chest 1989: 1241-1246.

  41. Willaert W, Daenen M, Bomans P, Verleden G, Decramer M. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur Respir J 2002; 19: 928-935.

  42. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006; 100: 1925-1932.

  43. Khirani S, Georgopoulos D, Rossi A, Moxham J. Ventilator support in chronic obstructive pulmonary disease: invasive and noninvasive. Eur Respir Mon 2006; 38: 401-429.

  44. Dhand R, Duarte AG, Jubran A, Jenne JW, Fink JB, Fahey PJ, Tobin MJ. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med 1996; 154: 388-393.

  45. Nava S, Karakurt S, Rampulla C, Braschi A, Fanfulla F. Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study. Intensive Care Med 2001; 27: 1627-1635.

  46. Barnes PJ. Chronic obstructive pulmonary disease. 12: New treatments for COPD. Thorax 2003; 58: 803-808.

  47. Dhand R, Tobin MJ. Bronchodilator delivery with metered-dose inhalers in mechanically-ventilated patients. Eur Respir J 1996; 9: 585-595.

  48. Wrenn K, Slovis CM, Murphy F, Greenberg RS. Aminophylline therapy for acute bronchoespastic disease in the emergency room. Ann Intern Med 1991; 115: 241-247.

  49. Rice KL, Leatherman JW, Duane PG, Snyder LD, Harmnon KR, Abel J, Niewoehner DE. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Ann Intern Med 1987; 107: 305-309.

  50. Lloberes P, Ramis L, Montserrat JM, Serra J, Campistol J, Picado C, Agusti-Vidal A. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988; 1: 536-539.

  51. Barbera JA, Reyes A , Roja J, Montserrat JM, Wagner PD, Rodriguez-Roisin R. Effect of intravenously administered aminophylline on ventilation perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145: 1328-1333.

  52. Barr RG, Rowe BH, Camargo CA. Methylxantines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003: CD002168.

  53. Duffy N, Walker P, Diamontea F, Calverley PM, Davies L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Thorax 2005; 60: 713-717.

  54. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002; 99: 8921-8926.

  55. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695.

  56. Ito K, Ito M, Elliott MW, Ito K, Ito M, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-1976.

  57. Barnes PJ. Theophylline for COPD. Reinstatement in the light of new evidence? Thorax 2006; 61: 742-744.

  58. Hirano T, Yamagata T, Gohda M, Yamagata Y, Ichikawa T, Yanagisawa S, Ueshima K, Akamatsu K, Nakanishi M, Matsunaga K, Minakata Y, Ichinose M. Inhibition of reactive nitrogen species production in COPD airways: comparison between inhaled corticosteroid and oral theophylline. Thorax 2006; 61: 761-766.

  59. Singh JM, Palda VA, Stanbrook MB, Chapman KR. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med 2002; 162: 2527-2536.

  60. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005: CD001288.

  61. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern med 1980; 92: 753-757.

  62. Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled trial of methylprednisolone in the treatment of acute exacerbations of COPD. Chest 1989; 95: 563-567.

  63. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407-412.

  64. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618-2625.

  65. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of veterans affairs cooperative study group. N Engl J Med 1999; 24(340): 1941-1947.

  66. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354: 456-460.

  67. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698-703.

  68. McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001; 119: 1190-1209.

  69. Moretti M, Fabbri LM, Clini E. Water-electrolyte imbalances in acute exacerbations of chronic obstructive pulmonary disease. En acute exacerbations of chronic obstructive pulmonary disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 265-279.

  70. Broekhuizen R, Creutzberg EC, Schols AMWJ. Metabolism and nutrition In acute exacerbations of chronic obstructive pulmonary disease. En acute exacerbations of chronic obstructive pulmonary disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 281-304.

  71. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322: 1271-1274.

  72. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O’Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T; ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390-1413.

  73. Greenstone M, Lasserson TJ. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003: CD000223.

  74. Barbera JA, Roca J, Ferrer A, Felez MA, Diaz O, Roger N, Rodriguez-Roisin R. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1285-1291.

  75. Aubier M, Murciano D, Milic-Emili J, Touaty E, Daghfous J, Pariente R, Derenne JP. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980; 122: 747-754.

  76. Moloney ED, Kiely JL, McNicholas WT. Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic pulmonary disease. Lancet 2001; 357: 526-528.

  77. O’Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006; 61: 354-361.

  78. Stevenson NJ, Walker PP, Costello RW, Calverey PMA. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1510-1516.

  79. Robinson TD, Freiberg DB, Regnis JA, Young IH. The role of hipoventilation and ventilation-perfusion redistribution in oxygen induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1524-1529.

  80. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, Simonneau G, Benito S, Gasparetto A, Lemaire F, Isabey D, Harf A. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817-822.

  81. Plant PK, Owen JL, Elliot MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomized controlled trial. Lancet 2000; 355: 1931-1935.

  82. Lightowler JV, Wedzicha JA, Elliot MW, Ram FS. Non-invasivave positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease. Cochrane systematic review and meta-analysis. BMJ 2003; 185-197.

  83. Elliott MW. Noninvasive ventilation in acute exacerbations of chronic obstructive pulmonary disease. In: Acute exacerbations of chronic obstructive pulmonary disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 405-424.

  84. Plant PK, Owen JL, Elliott MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. Thorax 2001; 56: 708-712.

  85. Esteban A, Anzueto A, Frutos F, Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE, Benito S, Epstein SK, Apezteguia C, Nightingale P, Arroliga AC, Tobin MJ; Mechanical Ventilation International Study Group. Characteristics and outcomes in adult patients receiving mechanical ventilation. A 28-day international study. JAMA 2002; 287: 345-355. –Véase comentarios en JAMA. 2002; 287: 1805.

  86. Dolan S, Varkey B. Prognostic factors in chronic obstructive pulmonary disease. Curr Op Pulm Med 2005; 11: 149-152.

  87. Purro A, Appendini L, De Gaetano A, Gudjonsdottir M, Donner CF, Rossi A. Physiologic determinants of ventilator dependence in long-term mechanically ventilated patients. Am J Respir Crit Care Med 2000; 161: 1115-1123.

  88. Nava S. Ambrosino N, Clini E, Prato M, Orlando G, Vitacca M, Brigada P, Fracchia C, Rubini F. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. Ann Intern Med 1998; 128: 721-728.

  89. Squadrone E, Frigerio P, Fogliati C, Gregoretti C, Conti G, Antonelli M, Costa R, Baiardi P, Navalesi P. Noninvasive versus invasive ventilation in COPD patients with severe acute respiratory deemed to require ventilatory assistance. Intensive Care Med 2004; 30: 1303-1310.

  90. Georgopoulos D, Rossi A. Invasive mechanical ventilation in acute exacerbation of chronic obstructive pulmonary disease. En acute exacerbations of chronic obstructive pulmonary disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 425-473.

  91. Douglas IV, Schmidt GA, Hall JB. Acute-on chronic respiratory failure. In: Principles of Critical Care. Hall JB, Schmidt GA, Wood LDH. Tercera edición, McGraw Hill 2005: 549-565.

  92. Jubran A, Tulaimat A. Weaning from the ventilator. In: Acute exacerbations of chronic obstructive pulmonary disease. Editado por Siafakas NM, Anthonisen NR, Georgopoulos D. Marcel Dekker, Inc. 2004: 475-506.

  93. Ambrosino N, Simonds AK. Mechanical ventilation. In: Muir JF, Ambrosino N, Simonds AK. Pulmonary Rehabilitation. Eur Respir Mono 2000; 13: 155-176.

  94. Laghi F, D’Alfonso N, Tobin MJ. Pattern of recovery from diaphragmatic fatigue over 24 hours. J Appl Physiol 1995; 79: 539-546.

  95. Manthous CA, Chatila W. Prolonged weakness after withdrawal of atracurium. Am J Respir Crit Care Med 1994; 150: 1441-1443.

  96. McEwen A, Hajek P, McRobbie H, West R. Manual of smoking cessation: a guide for counsellors and practitioners. Blackwell Publishing. 2006: 33-56.

  97. Man WD, Polkey MI, Donaldson N, Gray BJ, Moxham J. Community pulmonary rehabilitation after hospitalization for acute exacerbations of chronic obstructive pulmonary disease: randomized controlled study. BMJ 2004; 329: 1209

  98. Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality-a systematic review. Respiratory Research 2005; 6: 54-66.

  99. Mueller C, Laule-Kilian K, Frana B, Rodriguez D, Rudez J, Scholer A, Buser P, Pfisterer M, Perruchoud AP. The use of B-type natriuretic peptide in the management of elderly patients with acute dyspnoea. J Intern Med 2005; 258: 77-85.

  100. Hurst JR, Wedzicha JA. Exacerbation of obstructive lung diseases: therapy. Eur Respir Mon 2006; 36: 16-33.




2020     |     www.medigraphic.com